Communications Medicine (Oct 2022)
Data-driven analysis of a validated risk score for ovarian cancer identifies clinically distinct patterns during follow-up and treatment
Abstract
Enroth et al. validate their previously developed 11-biomarker plasma protein-based risk-score for distinguishing benign vs. malignant ovarian tumors. The risk score is found to be informative of treatment outcome and predictive of 5-year survival.